{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:05:52Z","timestamp":1786446352306,"version":"build-2736575974"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177810","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T19:49:11Z","timestamp":1495741751000},"page":"e0177810","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes"],"prefix":"10.1371","volume":"12","author":[{"given":"Nalini","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Illingworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Kodialbail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Lear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-346X","authenticated-orcid":true,"given":"Alice C. N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"issue":"25","key":"ref1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"RH Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene Laherparepvec: First Global Approval","volume":"76","author":"SL Greig","year":"2016","journal-title":"Drugs"},{"key":"ref3","article-title":"Oncolytic Viruses in Cancer Treatment: A Review","author":"SE Lawler","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"e1117740","DOI":"10.1080\/2162402X.2015.1117740","article-title":"Trial Watch-Oncolytic viruses and cancer therapy","volume":"5","author":"J Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref5","article-title":"Oncolytic viruses-immunotherapeutics on the rise","author":"BA Keller","year":"2016","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"E Kelly","year":"2007","journal-title":"Mol Ther"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"BD Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"226","key":"ref8","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"D Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mt.2013.238","article-title":"Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy","volume":"22","author":"ST Workenhe","year":"2014","journal-title":"Mol Ther"},{"key":"ref10","article-title":"The efficacy of oncolytic adenovirus is mediated by T cell responses against virus and tumor in Syrian hamster model","author":"S Wang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor","volume":"3","author":"S Tahtinen","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"HL Kaufman","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"J Heo","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"DS Chen","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs\u2014from CTLA4 to PD1 to the next generations","volume":"15","author":"A Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"6165","key":"ref16","first-page":"1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"J Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/21678707.2016.1191348","article-title":"Pembrolizumab for the treatment of advanced melanoma","volume":"4","author":"MC Burns","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrclinonc.2015.237","article-title":"Melanoma in 2015: Immune-checkpoint blockade\u2014durable cancer control","volume":"13","author":"EI Buchbinder","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"10030","key":"ref19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"L Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"J Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"ref21","first-page":"267","article-title":"Immune checkpoint inhibitors: therapeutic advances in melanoma","volume":"3","author":"I Marquez-Rodas","year":"2015","journal-title":"Ann Transl Med"},{"issue":"21","key":"ref22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"MA Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"ref23","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"ref24","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","author":"FS Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-Related Adverse Events From Immune Checkpoint Inhibitors","volume":"100","author":"KA Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"JM Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","article-title":"Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges","volume":"48","author":"F Tartari","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"RC Carlisle","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref29","first-page":"301","article-title":"Striking out at disseminated metastases: the systemic delivery of oncolytic viruses","volume":"8","author":"K Fisher","year":"2006","journal-title":"Curr Opin Mol Ther"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"I Kuhn","year":"2008","journal-title":"PLoS One"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","article-title":"Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood","volume":"21","author":"Y Di","year":"2014","journal-title":"Gene Ther"},{"issue":"Suppl 4","key":"ref32","doi-asserted-by":"crossref","first-page":"iv367","DOI":"10.1093\/annonc\/mdu342.17","article-title":"A Phase I study of enadenotucirev, an onclytic Ad11\/Ad3 chimeric group B adenovirus, administered intravenously\u2014analysis of dose expansion and repeat cycle cohorts n patients with metastatic colorectal cancer (mCRC)","volume":"25","author":"E Calvo","year":"2014","journal-title":"Annals of Oncology"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.molmed.2012.07.007","article-title":"Recombinant viral vaccines for cancer","volume":"18","author":"R Cawood","year":"2012","journal-title":"Trends Mol Med"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/JVI.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"AJ Bett","year":"1993","journal-title":"J Virol"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ymthe.2005.07.696","article-title":"Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression","volume":"12","author":"F Jin","year":"2005","journal-title":"Mol Ther"},{"key":"ref36","article-title":"Fields Virology","author":"DM Knipe","year":"2013"},{"key":"ref37","first-page":"479","article-title":"Escape of non-enveloped virus from intact cells","author":"SW Bird","year":"2015","journal-title":"Virology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.3103","article-title":"A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumours","volume":"32","author":"E Calvo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"ref39","doi-asserted-by":"crossref","first-page":"TPS5611","DOI":"10.1200\/jco.2015.33.15_suppl.tps5611","article-title":"A phase I\/II studcy of Enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epthelial ovarian cancer","volume":"33","author":"I McNeish","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"ref40","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"JC Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref41","first-page":"223","article-title":"Preparation and titration of CsCl-banded adenovirus stocks","volume":"130","author":"AE Tollefson","year":"2007","journal-title":"Methods Mol Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1472-6750-11-124","article-title":"Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts","volume":"11","author":"SY Alcoser","year":"2011","journal-title":"BMC Biotechnol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T15:35:12Z","timestamp":1602171312000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177810"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177810","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}